TAK-615常用于研究肺纤维化，是一种LPA1受体的负变构调节剂。

TAK-615 is commonly used to study pulmonary fibrosis and is a negative allosteric modulator of LPA1 receptors.

TAK-615 specifically binds to membranes expressing the human LPA1 receptor with estimated Kd high affinity of 1.7 ± 0.5 nM and Kd low affinity of 14.5 ± 12.1 nM. TAK-615 is only able to partically inhibit the LPA response (~40% at 10 μM with an IC50 of 23 ± 13 nM in β-arrestin assay; 60% at 10 μM, IC50 of 91 ± 30 nM in calcuim mobilisation assay). [1]

1664335-55-0

C25H22FNO4

419.44

DMSO:120 mg/mL (286.10 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years